Biotech startup lands $1.8 million in funding

Scioto Biosciences, an Indianapolis-based, preclinical-stage company developing therapies to fight serious conditions in premature infants, has closed on $1.8 million in early-stage financing.

The investors include locally based Elevate Ventures, a private venture development organization; locally based BioCrossroads, a public-private collaboration that supports Indiana’s life-sciences sector; and Ohio-based Rev1 Ventures.

Scioto Biosciences, founded in 2017, is trying to use the technology to combat a condition in premature infants where the wall of the intestine is invaded by bacteria.

“We are delighted that a team of important investors has shown confidence in our microbiome platform technology and sees its commercialization potential,” Scioto Biosciences CEO Joe Trebley said.•

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.